Aadi appoints Scott Giacobello as CFO, replacing interim CFO Lance Thibault

Whitehawk Therapeutics, Inc.

Scott Giacobello appointed CFO and Treasurer, effective Nov 28, 2021; part-time from Nov 1.
Compensation: $450k base salary, bonus up to 45% of base, and option for 200k shares vesting over 4 years.
Giacobello was CFO of GW Pharma (acquired by Jazz for $7.2B); led EPIDIOLEX launch with $296M first-year sales.
Company faces PDUFA date Nov 26, 2021 for lead drug FYARRO in malignant PEComa.
Lance Thibault, interim CFO since July 2021, will leave the role on the effective date.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Scott Giacobello

Chief Financial Officer and Treasurer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2021-11-28
Filed: November 1, 2021, 7:59 PM ET

appointed Scott Giacobello as its Chief Financial Officer and Treasurer, effective November 28, 2021

Departed (interim)

Lance Thibault

interim Chief Financial Officer

WHWK · Whitehawk Therapeutics, Inc.

Effective: 2021-11-28
Successor: Scott Giacobello
Filed: November 1, 2021, 7:59 PM ET

Lance Thibault, who has served as the interim Chief Financial Officer since July 2021, will cease to be the interim Chief Financial Officer of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Scott Giacobello was appointed as Chief Financial Officer and Treasurer at Whitehawk Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer and Treasurer

Exact text from the filing

appointed Scott Giacobello as its Chief Financial Officer and Treasurer, effective November 28, 2021

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Lance Thibault departed as interim Chief Financial Officer at Whitehawk Therapeutics, Inc..

Action: cease to be the interim Chief Financial Officer
Role: interim Chief Financial Officer

Exact text from the filing

Lance Thibault, who has served as the interim Chief Financial Officer since July 2021, will cease to be the interim Chief Financial Officer of the Company.

View on SEC.gov

Whitehawk Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-21-315472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.